Home > Healthcare > Medical Devices > Diagnostic Devices > Hemato Oncology Testing Market
Hemato Oncology Testing Market Size
- Report ID: GMI10902
- Published Date: Aug 2024
- Report Format: PDF
Hemato Oncology Testing Market Size
Hemato Oncology Testing Market size was valued at USD 3.2 billion in 2023 growing at a CAGR of 14.2% from 2024 to 2032. The market's growth is primarily fueled by the rising prevalence of hematological malignancies, such as myeloma and lymphoma, driving an increased demand for specialized diagnostic tests.
For example, a report from the American Cancer Society highlights that non-Hodgkin lymphoma (NHL) ranks among the most prevalent cancers in the U.S., constituting roughly 4% of all cancer cases. Moreover, the report notes that in 2023, approximately 80,620 individuals (44,590 males and 36,030 females) received NHL diagnosis. Consequently, advancements in diagnostic technology, coupled with heightened awareness of hematologic cancers and the advantages of early detection, have spurred a rise in screening and diagnostic testing, further propelling the market's growth.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Hemato Oncology Testing Market Size in 2023: | USD 3.2 Billion |
| Forecast Period: | 2024 – 2032 |
| Forecast Period 2024 – 2032 CAGR: | 14.2% |
| 2024 – 2032 Value Projection: | USD 10.4 Billion |
| Historical Data for: | 2021-2023 |
| No. of Pages: | 232 |
| Tables, Charts & Figures: | 405 |
| Segments covered: | Product & Service, Cancer Type, Technology, End-use, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Hemato oncology testing is a specialized medical diagnostic field dedicated to detecting, diagnosing, and monitoring blood-related cancers, including leukemia, lymphoma, and multiple myeloma. These tests aim to pinpoint genetic mutations, chromosomal abnormalities, and other biomarkers linked to hematologic malignancies.
Frequently Asked Questions (FAQ) :
Hemato Oncology Testing Market Scope
